Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for launching Olpruva, a new formulation of sodium phenylbutyrate approved as an oral suspension by the FDA, to treat patients with urea cycle disorders.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Perceptive Advisors
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 10, 2024
Details:
KP1077 (serdexmethylphenidate) is a prodrug of d-methylphenidate, which acts as dopamine & norepinephrine transporter antagonists. It is being evaluated for the treatment of idiopathic hypersomnia.
Lead Product(s): Serdexmethylphenidate
Therapeutic Area: Sleep Product Name: KP1077
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
BRX-345 (arimoclomol) is a first in class investigational HSF1 activator, which is being evaluated in phase 2/3 clinical trials for the treatment of Niemann-Pick disease type C.
Lead Product(s): Arimoclomol
Therapeutic Area: Rare Diseases and Disorders Product Name: BRX-345
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Arimoclomol is a first in class investigational HSF1 activator, which is under phase 2/3 clinical development for the treatment of Niemann-Pick disease type C.
Lead Product(s): Arimoclomol
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
Arimoclomol is a first in class investigational HSF1 activator, which is under phase 2/3 clinical development for the treatment of Niemann-Pick disease type C.
Lead Product(s): Arimoclomol
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of urea cycle disorders.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acer Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 20, 2023
Details:
KP1077 is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate.
Lead Product(s): Serdexmethylphenidate
Therapeutic Area: Sleep Product Name: KP1077
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of UCDs.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acer Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 31, 2023
Details:
KP1077 is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate.
Lead Product(s): Serdexmethylphenidate
Therapeutic Area: Sleep Product Name: KP1077
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
KP1077 is Zevra’s lead clinical candidate being developed to treat idiopathic hypersomnia (“IH”) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (“SDX”), Zevra’s proprietary prodrug of d-methylphenidate (“d-MPH”).
Lead Product(s): Serdexmethylphenidate
Therapeutic Area: Sleep Product Name: KP1077
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023